Most material SEC filings — July 17, 2026

Director SUMITOMO MITSUI FINANCIAL GROUP, INC. (JEF) bought 5.9M shares (~$318.7M) on the open market (41% of holdings). Open-market insider purchase — historically a bullish signal.

Kalaris Therapeutics announced expanded Phase 1a SAD results for TH103 in neovascular AMD (17 treatment-naive + 3 treatment-experienced patients, all completed 6-month follow-up). Key findings: mean 9.2-letter BCVA improvement at Month 1; 27–53× lower plasma Cmax than leading anti-VEGF agents; 29% of patients required no retreatment over 6 months, 41% not retreated until ≥4 months. Safety: no IOI cases at 2.5 mg with manufacturing batch #2; one transient IOI at 5 mg. Phase 1b/2 enrollment ongoing; preliminary data expected 1H 2027; cash runway extends to Q4 2027.